Transgene provides business and financial update for Q1 2024

information fournie par Boursorama CP •14/05/2024 à 17:45

TG4050: Exciting Phase I data presented at AACR 2024 demonstrating first signs of clinical benefit in adjuvant setting for head and neck cancer - Phase II part of randomized trial to start in coming weeks

New clinical data expected on TG4001, TG6050 and BT-001 in H2 2024

Financial visibility until Q4 2025

Strasbourg, France, May 14, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today provides a business update, including its financial position as of March 31, 2024.

.../...